Skip to main content

Animations

MJFF Publications

6981 - 6990 of 8808 Results
Title
Year
  • Year
  • 2024
  • 2023
  • 2011
  • 2023
  • 2025
  • 2020
  • 2023
  • 2018
  • 2014
  • 2020
  • Summary Details
    OPEN
    Title: Activation and Purification of ß‐Glucocerebrosidase by Exploiting its Transporter LIMP‐2 – Implications for Novel Treatment Strategies in Gaucher's and Parkinson's Disease
    Journal Name: Advanced Science
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1002/advs.202401641
    Citation Count: 3
  • Summary Details
    RESTRICTED
    Title: A novel brain penetrant c-Abl tyrosine kinase inhibitor: Paving a path forward to success in disease modification in Parkinson's disease
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2023.105325
    Citation Count: 0
  • Summary Details
    OPEN
    Title: Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case–control study
    Journal Name: The Lancet Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/s1474-4422(11)70175-2
    Citation Count: 325
  • Summary Details
    OPEN
    Title: Effects of Parkin on the Mitochondrial Genome in the Heart and Brain of Mitochondrial Mutator Mice
    Journal Name: Advanced Biology
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.1002/adbi.202300154
    Citation Count: 2
  • Summary Details
    OPEN
    Title: A Novel α‐Synuclein K58N Missense Variant in a Patient with Parkinson's Disease
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1002/mds.70030
    Citation Count: 0
  • Summary Details
    OPEN
    Title: Validation of human microRNA target pathways enables evaluation of target prediction tools
    Journal Name: Nucleic Acids Research
    Publisher: Oxford University Press (OUP)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1093/nar/gkaa1161
    Citation Count: 58
  • Summary Details
    OPEN
    Title: Perceived Discrimination in Health Care for LGBTQIA+ People Living With Parkinson’s Disease
    Journal Name: The Journals of Gerontology: Series B
    Publisher: Oxford University Press (OUP)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1093/geronb/gbad046
    Citation Count: 9
  • Summary Details
    OPEN
    Title: NMDA receptor blockade ameliorates abnormalities of spike firing of subthalamic nucleus neurons in a parkinsonian nonhuman primate
    Journal Name: Journal of Neuroscience Research
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/jnr.24230
    Citation Count: 26
  • Summary Details
    OPEN
    Title: Subthalamic nucleus—sensorimotor cortex functional connectivity in de novo and moderate Parkinson's disease
    Journal Name: Neurobiology of Aging
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.neurobiolaging.2014.07.004
    Citation Count: 47
  • Summary Details
    RESTRICTED
    Title: Pharmacokinetics and Biomarker Changes in NILO-PD, A Phase 2A Study of Nilotinib in Patients with Moderate to Advance Parkinson’s Disease (4418)
    Journal Name: Neurology
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1212/wnl.94.15_supplement.4418
    Citation Count: 0
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.